TABLE 1.
Primary cilia and drug resistance in cancer cell lines.
| Cancer cell lines | Drug resistance | Primary cilia length | Cells with primary cilia | References |
|---|---|---|---|---|
| A549 (Lung carcinoma) | Doxorubicin | increase | increase | Kim et al. (2022) |
| Paclitaxel | increase | increase | Kim et al. (2022) | |
| Dasatinib | increase | - | Kim et al. (2022) | |
| Trametinib | increase | increase | Jenks et al. (2018) | |
| Cisplatin | increase | - | Jenks et al. (2018) | |
| Carboplatin | - | - | Jenks et al. (2018) | |
| Vinflunine | increase | increase | Jenks et al. (2018) | |
| H2228 (Lung adenocarcinoma) | NVP-TAE | increase | increase | Jenks et al. (2018) |
| HCC4006 (Lung adenocarcinoma) | Erlotinib | increase | increase | Jenks et al. (2018) |
| PC-9 (Lung adenocarcinoma) | Afatinib | - | - | Jenks et al. (2018) |
| Erlotinib | - | - | Jenks et al. (2018) | |
| H23 (Lung adenocarcinoma) | Trametinib | increase | increase | Jenks et al. (2018) |
| H1792 (Lung adenocarcinoma) | Trametinib | - | increase | Jenks et al. (2018) |
| A204 (Muscle rhabdomyosarcoma) | Dasatinib | increase | - | Jenks et al. (2018) |
| PANC-1 (Pancreatic ductal adenocarcinoma) | Cisplatin | N.D. | increase | Chao et al. (2022) |
| MCF-7/ADR (Multidrug-resistant breast tumor cell line) | Doxorubicin (Adriamycin) | increase | increase | Kyun et al. (2020) |
N.D., not determined.